OncoMatch/Clinical Trials/NCT06892548
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Is NCT06892548 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including BNT324 and BNT327 for advanced lung cancer.
Treatment: BNT324 · BNT327 — This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: B7H3 targeted therapy
Prior treatment with B7-H3 targeted therapy
Allowed: AGA positive
Participants with AGA-positive disease must have received targeted therapy prior to enrollment in this study
Allowed: AGA negative
AGA negative
Allowed: PD-L1 (CD274) any or no expression
Participants with NSCLC are eligible with any or no PD-L1 expression
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: targeted therapy — AGA-positive disease
Participants with AGA-positive disease must have received targeted therapy prior to enrollment in this study
Cannot have received: B7-H3 targeted therapy
Prior treatment with B7-H3 targeted therapy
Cannot have received: antibody-drug conjugate with topoisomerase inhibitor payload (datopotamab deruxtecan, trastuzumab deruxtecan)
Exception: This exclusion applies to participants in the first-line/treatment-naïve cohorts in the advanced/metastatic setting. Prior treatment with ADC with topoisomerase inhibitor payload is only allowed for participants in the second-line plus cohorts in the advanced/metastatic setting.
Prior treatment with ADC with topoisomerase inhibitor (e.g., datopotamab deruxtecan, trastuzumab deruxtecan)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Arizona · Phoenix, Arizona
- Precision NextGen Oncology and Research Center · Beverly Hills, California
- Cedars Sinai Medical Center · Los Angeles, California
- UCLA - David Geffen School of Medicine · Santa Monica, California
- Mayo Clinic in Florida · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify